All In Biotech

Drug Trial Radar · NCT00057343

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared With Rituxan Alone in Patients With Relapsed or Refractory Follicular NHL

Last checked: Nov 20, 2026Latest source record: Sep 12, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

400

Actual

Start

Mar 2003

Primary completion

Not stated

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Apr 1, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

  • Zevalin (ibritumomab tiuxetan)Drug

  • Rituxan (rituximab)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival

Locations

67 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Bakersfield, California

  • Research Site

    Concord, California

  • Research Site

    Duarte, California

  • Research Site

    Loma Linda, California

  • Research Site

    Los Angeles, California

  • Research Site

    Mission Viejo, California

  • Research Site

    Newport Beach, California

  • Research Site

    Orange, California

  • Research Site

    Sacramento, California

  • Biogen Idec Incorporated

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    Santa Barbara, California

  • Research Site

    Vallejo, California

  • Research Site

    Farmington, Connecticut

  • Research Site

    Newark, Delaware

  • Research Site

    Jacksonville, Florida

  • Research Site

    Lakeland, Florida

  • Research Site

    Boise, Idaho

  • Research Site

    Coeur d'Alene, Idaho

  • Research Site

    Aurora, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Evanston, Illinois

  • Research Site

    Harvey, Illinois

  • Research Site

    Maywood, Illinois

  • Research Site

    Urbana, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Munster, Indiana

  • Research Site

    Kansas City, Kansas

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Detroit, Michigan

  • Research Site

    Flint, Michigan

  • Research Site

    Royal Oak, Michigan

  • Research Site

    Saint Joseph, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Rochester, Minnesota

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.